

Special Issue

Maternal and Infant Vaccines

Message from the Guest Editors

Pregnancy and infancy are periods of increased vulnerability to infection. Vaccinating women during pregnancy has been shown to be effective in protecting against infections, while also providing protection for the fetus and the infant during early life. Vaccinating infants can be effective in protecting them from infections. This Special Issue on 'Maternal and Infant Vaccines' aims to collect recent evidence on vaccines administered to pregnant women and babies in the first year of life. We are pleased to invite you to submit manuscripts to this Special Issue related to the following themes:

- Uptake, safety and effectiveness of current vaccines;
- Immunogenicity of vaccines;
- Potential future vaccines that are currently undergoing clinical trials.

We look forward to receiving your contributions.

Guest Editors

Dr. Prabha Andraweera

1. Adelaide Medical School and The Robinson Research Institute, The University of Adelaide, Adelaide, Australia
2. Vaccinology and Immunology Research Trials Unit, Women's and Children's Hospital, Adelaide, SA 5006, Australia

Dr. Bing Wang

1. Adelaide Medical School and The Robinson Research Institute, The University of Adelaide, Adelaide, Australia
2. Vaccinology and Immunology Research Trials Unit, Women's and Children's Hospital, Adelaide, SA 5006, Australia

Deadline for manuscript submissions

20 September 2025



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/232949

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).